Active, not recruitingPhase 1NCT03257761

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Studying Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Southern California
Principal Investigator
Anthony El-Khoueiry, MD
University of Southern California
Intervention
Durvalumab(biological)
Enrollment
55 enrolled
Eligibility
18 years · All sexes
Timeline
20182026

Study locations (3)

Collaborators

National Cancer Institute (NCI) · Van Andel Research Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03257761 on ClinicalTrials.gov

Other trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

← Back to all trials